General - Molecular Intervention
Payments companies reported to CMS as associated with General - Molecular Intervention. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with General - Molecular Intervention, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with General - Molecular Intervention
These are the largest totals companies reported as associated with General - Molecular Intervention. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Divyesh Bhakta | Louisville, KY | Interventional Cardiology | $153.12 |
| Vipul Panchal | Louisville, KY | Cardiovascular Disease | $148.35 |
| Armand Rothschild | Louisville, KY | Cardiovascular Disease | $148.35 |
| Ibrahim Fahsah | Louisville, KY | Interventional Cardiology | $148.35 |
| Faraaz Rahman | Louisville, KY | Interventional Cardiology | $148.34 |
| Sreedevi Gondi | Louisville, KY | Interventional Cardiology | $148.34 |
| Brian Jefferson | Nashville, TN | Interventional Cardiology | $148.34 |
| Shanker Chandiramani | Louisville, KY | Cardiovascular Disease | $148.34 |
| Yuvraj Chowdhury | Louisville, KY | Cardiovascular Disease | $148.34 |
| Jacob Nunamaker | Louisville, KY | Interventional Cardiology | $148.34 |
Prescribed General - Molecular Intervention?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.